Место ингибиторов 5-редуктазы в химиопрофилактике рака предстательной железы

Автор: Сивков А.В., Жернов А.А., Кешишев Н.Г., Шкабко О.В.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 2, 2012 года.

Бесплатный доступ

Рак предстательной железы, химиопрофилактика, ингибитор 5α-редуктазы, финастерид, дутастерид

Короткий адрес: https://sciup.org/142188305

IDR: 142188305

Список литературы Место ингибиторов 5-редуктазы в химиопрофилактике рака предстательной железы

Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., Thun M.J. Cancer statistics, 2006//CA Cancer J Clin, 2006. Vol. 56, № 2. P. 106-130.
Аполихин О. И., Сивков А.В., Бешлиев Д.А., Солнцева Т.В., Комарова В.А., Зайцевская Е.В. Анализ урологической заболеваемости в Российской Федерации в 2002-2009 годах по данным официальной статистики//Экспериментальная и клиническая урология. 2011. № 1. С. 4-10.
Donavan J., Lane A., Hamdy M., et al. Evaluating screening and treatment for localised prostate cancer concurrently: the ProtecT study//Presented at the American Society of Clinical Oncology, Orlando, 2005.
Klotz L.H. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease//Can J Urol. 2005. Vol. 12, Suppl 1. P. 53-57.
Kelloff G.J., Boone C.W., Crowell J.A., Nayfield S.G., Hawk E., Malone W.F., Steele V.E., Lubet R.A., Sigman C.C. Risk biomarkers and current strate-Y gies for cancer chemoprevention//J Cell Biochem Suppl. 1996. Vol 25. P. 1-14.
Greenwald P. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials//J Cell Biochem Suppl 1996 Vol 25 P 29-36
Gormley G.J., Brawley O., Thompson I. The potential application of finasteride for chemoprevention of prostate cancer//Ann N Y Acad Sci 1995 Vol. 768. P. 163-169
Thorpe J.F., Jain S., Marczylo T.H., Gescher A.J., Steward W.P., Mellon J.K. A Review of Phase III Clinical Trials of Prostate Cancer Chemoprevention//Ann R Coll Surg Engl. 2007. Vol.89, № 3. P. 207-211.
Thompson I.M., Klein E.A., Lippman S.M., Coltman C.A., Djavan B. Preven tion of prostate cancer with finasteride: US/European perspective//Eur Urol. 2003.Vol. 44, № 6. P. 650-655.
Ishikawa S., Soloway M.S., Van der Zwaag R., Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer//J Urol. 1989. Vol. 141, № 5. P. 1139-1142.
Prehn R. T. On the prevention and therapy of prostate cancer by androgen administration//Cancer Res. 1999. Vol. 59, № 17. P. 4161-4164.
Schatzl G., Madersbacher S., Haitel A., Gsur A., Preyer M., Haidinger G., Gassner C., Ochsner M., Marberger M. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer//J Urol. 2003. Vol. 169, № 4. P. 1312-1315.
Bostwick D.G. Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation//Anat Pathol. 1998. № 3.P. 1-16
Yang X.J., Lecksell K., Short K., Gottesman J., Peterson L., Bannow J., Schell-hammer P.F., Fitch W.P., Hodge G.B., Parra R., Rouse S., Waldstreicher J., Epstein J.I. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group Proscar Long-Term Efficacy and Safety Study//Urology 1999 Vol 53, № 4.P 696-700.
Djavan B., Zlotta A., Schulman C., Teillac P., Iversen P., Boccon Gibod L., Bartsch G., Marberger M. Chemotherapeutic prevention studies of prostate cancer//J Urol, 2004. Vol. 171, № 2. Pt 2. P 10-13.
Klotz L., Drachenberg D., Fradet Y., Saad F., Trachtenberg J., Zlotta A. Gleason grading controversies: what the chemoprevention trials have taught us//Can Urol Assoc J, 2009. Vol. 3, Suppl 2. P. 115-120.
Rittmaster R.S., Fleshner N.E., Thompson I.M. Pharmacological Approaches to Reducing the Risk of Prostate Cancer//Eur Urol 2009 Vol 55, № 5 P 1064-1073
Sarvis J.A., Thompson I.M. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice//Curr Oncol Rep, 2008. Vol. 10, № 6. P 529-532.
Hamilton R.J., Freedland S.J. 5α-reductase inhibitors and prostate cancer pre vention: where do we turn now?//BMC Med 2011 Vol 9 P 105
Kulkarni G.S., Al-Azab R., Lockwood G., Toi A., Evans A., Trachtenberg J., Jewett M.A., Finelli A., Fleshner N.E. Evidence for a biopsy derived grade artifact among larger prostate glands//J Urol. 2006. Vol. 175. P 505-509.
Thompson I.M., Chi C., Ankerst D.P., Goodman P.J., Tangen C.M., Lippman S.M., Lucia M.S., Parnes H.L., Coltman C.A. Jr Effect of finasteride on the sensitivity of PSA for detecting prostate cancer//J Natl Cancer Inst. 2006. Vol. 98. P. 1128-1133.
Thompson I.M., Tangen C.M., Goodman P.J., Lucia M.S., Parnes H.L., Lippman S.M., Coltman C.A. Jr Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection//J Urol. 2007. Vol. 177. P. 1749-1752
Barnett S. Kramer, Karen L. Hagerty, Stewart Justman, Mark R. Somerfield, Peter C. Albertsen, William J. Blot, H. Ballentine Carter, Joseph P. Costantino, Jonathan I. Epstein, Paul A. Godley, Russell P. Harris, Timothy J. Wilt, Janet Wittes, Robin Zon, and Paul Schellhammer. Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology American Urological Association 2008 Clinical Practice Guideline//J Clin Oncol. 2009. Vol. 27, № 9 P. 1502-1516.
Clark R.V., Hermann D.J., Gabriel H., Wilson T.H., Morrill B.B., Hobbs S. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel, dual alpha reductase inhibitor//AUA 94th annual meeting. J Urol. 1999. Vol. 161, № 4, Suppl (N 1037) P 268
Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., Breed S., Somerville M., Rittmaster R. REDUCE Study Group Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial//J Urol. 2004. Vol. 172, № 4, Pt 1. P. 1314-131721.
Musquera M., Fleshner N.E., Finelli A., Zlotta A.R. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride//Expert Rev Anticancer Ther. 2008. Vol. 8, № 7. P. 1073-1079.
Thomas L.N., Douglas R.C., Vessey J.P., Gupta R., Fontaine D., Norman R.W., Thompson I.M., Troyer D.A., Rittmaster R.S., Lazier C.B. 5-alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium//J Urol. 2003. Vol. 170, № 5. P. 2019-2025
Roehrborn C.G, Boyle P., Nickel J.C., Hoefner K., Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia//Urology. 2002. Vol. 60. P. 434-441.
Gerald L. Andriole, M.D., David G. Bostwick, M.D., Otis W. Brawley, M.D., Leonard G. Gomella, M.D., Michael Marberger, M.D., Francesco Montorsi, M.D., Curtis A. Pettaway, M.D., Teuvo L. Tammela, M.D., Claudio Teloken, M.D., Ph.D., Donald J. Tindall, Ph.D., Matthew C. Somerville, M.S., Timothy H. Wilson, M.S., Ivy L. Fowler, B.S.N., and Roger S. Rittmaster, M.D. for the REDUCE Study Group Effect of Dutasteride on the Risk of Prostate Cancer//N Engl J Med. 2010. Vol. 362. P. 1192-1202.
Кудрявцев Ю.В., Сивков А.В., Ощепков В.Н., Сафаров Т.Р. Влияние ингибиторов 5А-П редуктазы на простатическую интраэпителиальную неоплазию предстательной железы//«Фундаментальные исследования в уронефрологии». Материалы Российской научной конференции с международным участием Изд-во Саратовского гос мед университета, 2009. С. 423-424.
Сивков А.В., Ощепков В.Н. Фармакотерапия доброкачественной гиперплазии и рака предстательной железы Финастерид: 20 лет клинической практики лечения больных аденомой предстательной железы//Consilium Medicum 2006 Т 8, № 4 C 36-39
Кудрявцев Ю.В., Романова Л.М. Морфологические изменения в ткани предстательной железы при доброкачественной гиперплазии/в кн. Доброкачественная гиперплазия предстательной железы. Под ред. Н.А. Лопаткина. М.:1999. С. 37-45.

Еще

Статья